drugset
drugset / Trial / NCT00425672

ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment

NCT00425672 ↗

Phase 1/2 Completed 15 enrolled University of Washington National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: ONTAK may be able to help reduce the type of cells that prevent other types of immune cells from attacking the breast cancer cells. PURPOSE: This phase I/II trial is studying the safety of ONTAK and its possible side effects to see how well it works in treating patients with advanced breast cancer that did not respond to previous treatment.

Timeline

Start
2005-09
Primary completion
2010-04
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject denileukin diftitox Protein / enzyme biologic — Intravenous

Indications

male breast carcinoma